[go: up one dir, main page]

PE20060764A1 - Composiciones farmaceuticas para el tratamiento y/o prevencion de enfermedades cardiovasculares - Google Patents

Composiciones farmaceuticas para el tratamiento y/o prevencion de enfermedades cardiovasculares

Info

Publication number
PE20060764A1
PE20060764A1 PE2005001480A PE2005001480A PE20060764A1 PE 20060764 A1 PE20060764 A1 PE 20060764A1 PE 2005001480 A PE2005001480 A PE 2005001480A PE 2005001480 A PE2005001480 A PE 2005001480A PE 20060764 A1 PE20060764 A1 PE 20060764A1
Authority
PE
Peru
Prior art keywords
prevention
treatment
acid
agent
alpha
Prior art date
Application number
PE2005001480A
Other languages
English (en)
Inventor
Jonathan David Bortz
Mitchell I Kirschner
David S Hermelin
Marc S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of PE20060764A1 publication Critical patent/PE20060764A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

REFERIDA A UNA COMPOSICION QUE COMPRENDE: A) UN AGENTE ANTI-INFLAMATORIO DE LA CELULA ENDOTELIAL TAL COMO ACIDOS GRASOS NATURALES OMEGA-3, ACIDOEICOSAPENTAENOICO, ACIDO ALFA-LINOLENICO, ENTRE OTROS; B)UN AGENTE ESTIMULANTE DE GENERACION DE OXIDO NITRICO TAL COMO ACIDO FOLICO, FOLATO, PRECURSORES DEL ACIDO FOLICO, ENTRE OTROS; C) UN AGENTE ANTI-OXIDANTE TAL COMO ACIDO ASCORBICO, ALFA-TOCOFEROL, VITAMINA A, ENTRE OTROS; Y D) UN AGENTE REDUCTOR DE AGREGACION DE PLAQUETAS TAL COMO PIRIDOXINO, PIRIDOXAMINA, METABOLITOS DE PIRIDOXAL, ENTRE OTROS. DICHA COMPOSICION ESTIMULA Y/O MANTIENE LA SALUD CARDIOVASCULAR MEDIANTE LA PREVENCION, ESTABILIZACION, REVERSION Y/O TRATAMIENTO DE UNA ENFERMEDAD DE LA ARTERIA CORONARIA Y/O UNA ENFERMEDAD CEREBROVASCULAR
PE2005001480A 2004-12-22 2005-12-16 Composiciones farmaceuticas para el tratamiento y/o prevencion de enfermedades cardiovasculares PE20060764A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/021,282 US20060135610A1 (en) 2004-12-22 2004-12-22 Cardiovascular compositions

Publications (1)

Publication Number Publication Date
PE20060764A1 true PE20060764A1 (es) 2006-08-16

Family

ID=36596911

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001480A PE20060764A1 (es) 2004-12-22 2005-12-16 Composiciones farmaceuticas para el tratamiento y/o prevencion de enfermedades cardiovasculares

Country Status (11)

Country Link
US (1) US20060135610A1 (es)
EP (1) EP1838323A4 (es)
JP (1) JP2008525441A (es)
CN (1) CN101123969A (es)
AR (1) AR052836A1 (es)
AU (1) AU2005322584A1 (es)
BR (1) BRPI0518565A2 (es)
CA (1) CA2594212A1 (es)
MX (1) MX2007007781A (es)
PE (1) PE20060764A1 (es)
WO (1) WO2006071342A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7399755B2 (en) * 2005-02-17 2008-07-15 Premier Micronutrient Corporation Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same
CN103058867B (zh) * 2005-05-04 2015-03-25 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
US20070299017A1 (en) * 2006-06-23 2007-12-27 Kanter Mitchell M Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
EP1882473A1 (en) 2006-07-28 2008-01-30 Indena S.P.A. Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs
US20080064702A1 (en) * 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
US8399516B2 (en) * 2006-11-01 2013-03-19 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
RU2009120568A (ru) * 2006-11-01 2010-12-10 Пронова Биофарма Норге Ас (No) Композиция
RU2507193C2 (ru) * 2006-11-01 2014-02-20 Пронова Биофарма Норге А/С Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar)
JP5552314B2 (ja) * 2006-11-01 2014-07-16 プロノヴァ バイオファーマ ノルゲ アーエス 新規脂質化合物
WO2008103370A1 (en) 2007-02-22 2008-08-28 Children's Hospital And Research Center At Oakland Fatty acid formulations and methods of use thereof
EP2217558A1 (en) * 2007-10-31 2010-08-18 Pronova Biopharma Norge AS New dha derivatives and their use as medicaments
EP2209377B8 (en) * 2007-11-06 2018-10-17 The Salk Institute For Biological Studies Use of vitamin d receptor agonists and precursors to treat fibrosis
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
US8586104B2 (en) * 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
US8784904B2 (en) * 2008-04-10 2014-07-22 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use
US8592439B2 (en) * 2008-08-07 2013-11-26 Spa Societa Prodotti Antibiotici S.P.A. Long-term treatment of symptomatic heart failure
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010064665A1 (ja) * 2008-12-01 2010-06-10 辻堂化学株式会社 治療剤
MX2011005330A (es) * 2008-12-04 2011-06-16 Sanofi Aventis Metodos y usos que implican la proteina 1 de union a hemo.
SMT202000079T1 (it) 2009-02-10 2020-03-13 Amarin Pharmaceuticals Ie Ltd Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
US20100239660A1 (en) * 2009-03-19 2010-09-23 Doughman Scott D Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions
PL2424356T3 (pl) 2009-04-29 2018-03-30 Amarin Pharmaceuticals Ireland Limited Stabilna farmaceutyczna kompozycja i sposoby jej stosowania
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2856959T3 (es) * 2009-06-15 2021-09-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina
BR122019016628B8 (pt) 2009-09-23 2021-07-27 Amarin Corp Plc uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
RU2606853C2 (ru) * 2010-03-04 2017-01-10 Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
US8563267B2 (en) * 2010-07-22 2013-10-22 Asia-Pacific Beiotech Developing, Inc. Lycogen extract, composition thereof and method for the treatment using the same
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
HK1203764A1 (en) 2012-01-06 2015-11-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
UA118015C2 (uk) 2012-06-29 2018-11-12 Амарін Фармасьютікалз Айрленд Лімітед Способи зменшення ризику розвитку серцево-судинної події у суб'єкта, що одержує терапію статином
CN102901788B (zh) * 2012-08-31 2014-09-10 江苏省农业科学院 叶黄素二琥珀酸酯的测定方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
MX2015014701A (es) 2013-04-24 2016-08-08 Salk Inst For Biological Studi Circuito genomico del receptor de vitamina d/smad que regula la compuerta de la respuesta fibrotica.
CN105451818A (zh) 2013-06-05 2016-03-30 萨克生物研究学院 治疗涉及cxcl12活性的疾病的维生素d受体激动剂
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MX390909B (es) * 2013-12-19 2025-03-21 Tassos Georgiou Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
CN106103678B (zh) 2014-03-17 2019-09-17 兴人生命科学株式会社 含有磷脂型α亚麻酸的组合物
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN104940933A (zh) * 2015-06-15 2015-09-30 青岛大学附属医院 一种用于预防治疗心血管疾病的药物
JP2018531936A (ja) * 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11978543B2 (en) * 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN111991386A (zh) 2018-09-24 2020-11-27 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
WO2020138556A1 (ko) * 2018-12-28 2020-07-02 경상대학교병원 혈관 확장 감소 억제용 의약 조성물
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697559A (en) * 1971-02-25 1972-10-10 Wisconsin Alumni Res Found 1,25-dihydroxycholecalciferol
US4097602A (en) * 1974-11-29 1978-06-27 Silver Melvin J Method of inhibiting blood platelet aggregation
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
US5405613A (en) * 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
GB9404483D0 (en) * 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US5922704A (en) * 1997-12-24 1999-07-13 Feeling Fine Company Llc Optimal nutritional supplement for men
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
NO312973B1 (no) * 1999-02-17 2002-07-22 Norsk Hydro As Lipase-katalysert forestring av marine oljer
US6569857B1 (en) * 1999-05-03 2003-05-27 Drugtech Corporation Dietary supplement
NO310113B1 (no) * 1999-08-11 2001-05-21 Norsk Hydro As Fremgangsmåte for utvinning av flerumettede fettsyrer fra ureakomplekser
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
BR0001794A (pt) * 2000-05-15 2001-12-26 Laboratorios Biosintetica Ltda Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
US6579544B1 (en) * 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
WO2002043659A2 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
WO2002043662A2 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Dietary composition containing conjugated linoleic acid and calcium for improved health
JP3533605B2 (ja) * 2001-12-06 2004-05-31 すこやか食品株式会社 血圧降下、心臓強化、動脈硬化防止、血管保護、抗疲労、運動機能向上、エネルギー代謝効率向上、抗酸化などの諸効果を有する栄養補助食品。
US6551629B1 (en) * 2002-07-03 2003-04-22 Vitacost.Com, Inc. Cardiovascular promotion and maintenance composition
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
FR2869502B1 (fr) * 2004-04-28 2006-07-21 Cybelia Soc Par Actions Simpli Aliments pour poules pondeuses, procede d'alimentation et oeuf enrichi en elements essentiels

Also Published As

Publication number Publication date
BRPI0518565A2 (pt) 2008-11-25
WO2006071342A2 (en) 2006-07-06
MX2007007781A (es) 2007-08-22
AR052836A1 (es) 2007-04-04
EP1838323A4 (en) 2008-06-18
US20060135610A1 (en) 2006-06-22
WO2006071342A3 (en) 2007-08-09
AU2005322584A1 (en) 2006-07-06
JP2008525441A (ja) 2008-07-17
CA2594212A1 (en) 2006-07-06
EP1838323A2 (en) 2007-10-03
CN101123969A (zh) 2008-02-13

Similar Documents

Publication Publication Date Title
PE20060764A1 (es) Composiciones farmaceuticas para el tratamiento y/o prevencion de enfermedades cardiovasculares
MX2018011278A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
CL2020000747A1 (es) Formulaciones de niraparib.
CY1124473T1 (el) Φυτοσυμπλοκα απο citrus bergamia
MX395710B (es) Composiciones gomosas de multicomponentes con nucleo duro.
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
DOP2009000155A (es) Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38
PE20130063A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
MX2022001225A (es) Metodo para mejorar la salud digestiva.
AR097067A1 (es) Formulación que comprende un agente hipolipidémico
CO2019008053A2 (es) Agente terapéutico para enfermedades del hígado
PA8544401A1 (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
GB2492680A (en) Oral supplement
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
PE20091900A1 (es) Una formulacion farmaceutica solida
PE20221272A1 (es) Agente supresor del sabor desagradable
AR094224A1 (es) Composicion farmaceutica en forma de una suspension oral
MX2021014555A (es) Composiciones y métodos de tratamiento de la retinopatía.
AR101673A1 (es) Composición para el tratamiento de neuropatías y del dolor neuropático

Legal Events

Date Code Title Description
FC Refusal